Tackling ischaemic heart disease in rheumatoid arthritis

Rheumatology

Volumn 42, Issue 5, 2003, Pages 607-613

  Kitas, G D ^a   Erb, N ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIHYPERTENSIVE AGENT; ANTIMALARIAL AGENT; ANTIRHEUMATIC AGENT; DICLOFENAC; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FOLIC ACID; IBUPROFEN; METHOTREXATE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN SYNTHASE INHIBITOR; SALAZOSULFAPYRIDINE;

CARDIOVASCULAR RISK; CAUSE OF DEATH; CORONARY ARTERY ATHEROSCLEROSIS; DISEASE ASSOCIATION; DRUG ANTAGONISM; EDITORIAL; HOMOCYSTINURIA; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; NEPHROTOXICITY; PHYSICAL DISABILITY; PREVALENCE; PRIORITY JOURNAL; RHEUMATIC HEART DISEASE; RHEUMATOID ARTHRITIS; RISK FACTOR; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; AGED; FEMALE; HEART MUSCLE ISCHEMIA; MALE; MIDDLE AGED;

AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CORONARY ARTERIOSCLEROSIS; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; RISK FACTORS;

EID: 0043280989     PISSN: 14620324     EISSN: None     Source Type: Journal    
DOI: 10.1093/rheumatology/keg175     Document Type: Editorial

References (141)

1. Cobb S, Anderson F, Bayer W. Length of life and cause of death in rheumatoid arthritis. N Engl J Med 1953; 249:553-6.
2. Goodson N. Coronary artery disease and rheumatoid arthritis. Curr Opin Rheumatol 2002;14:115-20.
3. van Doornum S, McColl G, Wicks IP. Accelerated atherosclerosis. An extraarticular feature of rheumatoid arthritis? Arthritis Rheum 2002;46:862-73.
4. Pincus T, Callahan LF. Rheumatology function tests: grip strength, walking time, button test and questionnaires document predict longterm morbidity and mortality in rheumatoid arthritis. J Rheumatol 1992;19:1051-7.
5. Pincus T, Callahan LF. Taking mortality in rheumatoid arthritis seriously: predictive markers, socioeconomic status and comorbidity. J Rheumatol 1986;13:841-5.
6. Gabriel SE, Crowson CS, O'Fallon WM. Mortality in rheumatoid arthritis: have we made an impact in 4 decades? J Rheumatol 1999;26:2529-33.
7. Ward MM. Recent improvements in survival in patients with rheumatoid arthritis: better outcomes or different study designs? Arthritis Rheum 2001;44:1467-9.
8. Reilly PA, Cosh JA, Maddison PJ, Rasker JJ, Silman AJ. Mortality and survival in rheumatoid arthritis: a 25 year prospective study of 100 patients. Ann Rheum Dis 1990; 49:363-9.
9. Linos A, Worthington JW, O'Fallon WM, Kurland LT. The epidemiology of rheumatoid arthritis in Rochester, Minnesota: a study of incidence, prevalence, and mortality. Am J Epidemiol 1980;111:87-98.
10. Lindqvist E, Eberhardt K. Mortality in rheumatoid arthritis patients with disease onset in the 1980s. Ann Rheum Dis 1999;58:11-4.
11. Sokka T, Mottonen T, Hannonen P. Mortality in early 'saw-tooth' treated rheumatoid arthritis patients during the first 8-14 yr. Scand J Rheumatol 1999;28:282-7.
12. Kroot EJ, van Leeuwen MA, van Rijswijk MH et al. No increased mortality in patients with rheumatoid arthritis: up to 10 yr of follow up from disease onset. Ann Rheum Dis 2000;59:954-8.
13. Riise T, Jacobsen BK, Gran JT et al. Total mortality is increased in rheumatoid arthritis: a 17 year prospective study. Clin Rheumatol 2001;20:123-7.
14. Monson RR, Hall AP. Mortality among arthritics. J Chron Dis 1976;29:459-67.
15. Allebeck P, Ahlbom A, Allander E. Increased mortality among persons with rheumatoid arthritis, but where RA does not appear on death certificate - eleven year follow-up of an epidemiological study. Scand J Rheumatol 1981; 10:301-6.
16. Prior P, Symmons DPM, Scott DL, Brown R, Hawkins CF. Cause of death in rheumatoid arthritis. Br J Rheumatol 1984;23:92-9.
17. Mutru O, Laakso M, Isomaki H et al. Ten year mortality and causes of death in patients with rheumatoid arthritis. Br Med J 1985;290:1797-9.
18. Mutru O, Laakso M, Isomaki H, Koota K. Cardiovascular mortality in patients with rheumatoid arthritis. Cardiology 1989;76:71-7.
19. Jacobsson LTH, Knowler WC, Pillemer S et al. Rheumatoid arthritis and mortality: a longitudinal study in Pima Indians. Arthritis Rheum 1993;36:1045-53.
20. Myllykangas-Luosujarvi R, Aho K, Kautianen H, Isomaki H. Cardiovascular mortality in women with rheumatoid arthritis. J Rheumatol 1995;22:1065-7.
21. Turesson C, Jacobsson L, Bergstrom U. Prevalence and mortality of extraarticular rheumatoid arthritis. Arthritis Rheum 1997;40:741.
22. Wallberg-Jonsson S, Ohman ML, Rantapaa-Dahlqvist S. Cardiovascular morbidity and mortality in patients with seropositive rheumatoid arthritis in Northern Sweden. J Rheumatol 1997;24:445-51.
23. Symmons DPM, Jones MA, Scott DL, Prior P. Long-term mortality outcomes in patients with rheumatoid arthritis: early presenters continue to do well. J Rheumatol 1998;25:1072-7.
24. Kvalvik AG, Jones MA, Symmons DPM. Mortality in a cohort of Norwegian patients with rheumatoid arthritis followed from 1977 to 1992. Scand J Rheumatol 2000; 29:29-37.
25. Goodson NJ, Wiles NJ, Lunt M et al. Increased mortality in seropositive patients during the early years of inflammatory polyarthritis [abstract]. Rheumatology 2001;40 (Suppl. 1):71.
26. Mikuls TR, Saag KG. Comorbidity in rheumatoid arthritis. Rheum Dis Clin North Am 2001;27:283-303.
27. Kroot EJJA, van Gestel AM, Swinkels HL et al. Chronic comorbidity in patients with early rheumatoid arthritis: a descriptive study. J Rheumatol 2001;28:1511-7.
28. Kitas GD, Banks MJ, Bacon PA. Cardiac involvement in rheumatoid disease. Clin Med JRCPL 2001;1:18-21.
29. Gabriel SE, Crowson CS, O'Fallon WM. Comorbidity in arthritis. J Rheumatol 1999;26:2475-9.
30. del Rincon I, Williams K, Stern MP, Freeman GL, Escalante A. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 2001; 44:2737-45.
31. Banks M, Flint J, Bacon PA, Kitas GD. Rheumatoid arthritis is an independent risk factor for ischaemic heart disease [abstract]. Arthritis Rheum 2000;43(Suppl. 9):S385.
32. Wislowska M, Sypula S, Kowalick I. Echocardiographic findings, 24 hour electrocardiographic Holter monitoring in patients with rheumatoid arthritis according to Steinbrocker's criteria, functional index, value of Waaler-Rose titer and duration of disease. Clin Rheumatol 1998;17:369-77.
33. Banks MJ, Pace A, Kitas GD. Acute coronary syndromes present atypically and recur more frequently in rheumatoid arthritis than matched controls [abstract]. Arthritis Rheum 2001;44(Suppl.):S53.
34. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339:229-34.
35. Ismail AA, Gill GV. The epidemiology of type 2 diabetes and its current measurement. Bailliere's Clin Endocrinol Metab 1999;13:197-220.
36. Fisher M. Diabetes and myocardial infarction. Bailliere's Clin Endocrinol Metab 1999;13:331-43.
37. Castells I, Salinas I, Rius F et al. Inducible myocardial ischaemia in asymptomatic type 2 diabetic patients. Diabetes Res Clin Practice 2000;49:127-33.
38. Kuller LH, Velentgas P, Barzilay J, Beauchamp NJ, O'Leary DH, Savage PJ. Diabetes mellitus. Subclinical cardiovascular disease and risk of incident cardiovascular disease and all cause mortality. Arterioscl Thromb Vasc Biol 2000;20:823-9.
39. Barzilay JI, Spiekerman CF, Kuller LH et al. Prevalence of clinical and isolated subclinical cardiovascular disease in older adults with glucose disorders: the cardiovascular health study. Diabetes Care 2001;24:1233-9.
40. Jonsson SW, Backman C, Johnson O et al. Increased prevalence of atherosclerosis in patients with medium term rheumatoid arthritis. J Rheumatol 2001;28:2597-602.
41. Hernandez Avila M, Liang MH, Willett WC et al. Reproductive factors, smoking, and the risk for rheumatoid arthritis. Epidemiology 1990;1:285-91.
42. Heliovaara M, Aho K, Aromaa A, Knekt P, Reunanen A. Smoking and risk of rheumatoid arthritis. J Rheumatol 1993;20:1830-5.
43. Voigt LF, Koepsell TD, Nelson JL, Dugowson CE, Daling JR. Smoking, obesity, alcohol consumption and the risk of rheumatoid arthritis. Epidemiology 1994;5:525-32.
44. Silman AJ, Newman I, MacGregor AJ. Cigarette smoking increases the risk of rheumatoid arthritis: results from a nationwide study of disease-discordant twins. Arthritis Rheum 1996;39:732-5.
45. Symmons DPM, Bankhead CR, Harrison BI et al. Blood transfusion, smoking, and obesity as risk factors for the development of rheumatoid arthritis: results from a primary care-based incident case-control study in Norfolk, England. Arthritis Rheum 1997;40:1955-61.
46. Uhlig T, Hagen KB, Kvien TK. Current tobacco smoking, formal education, and the risk of rheumatoid arthritis. J Rheumatol 1999;26:47-54.
47. Hutchinson D, Shepstone L, Moots R, Lear JT, Lynch MP. Heavy cigarette smoking is strongly associated with rheumatoid arthritis (RA), particularly in patients without a family history of RA. Ann Rheum Dis 2001;60:223-7.
48. Saag KG, Cerhan JR, Kolluri S, Ohashi K, Hunninghake GW, Schwartz DA. Cigarette smoking and rheumatoid arthritis severity. Ann Rheum Dis 1997;56:463-9.
49. Wolfe F. The effect of smoking on clinical, laboratory, and radiographic status in rheumatoid arthritis. J Rheumatol 2000;27:630-7.
50. Masdottir B, Jonsson T, Manfredsdottir V et al. Smoking, rheumatoid factor isotypes and severity of rheumatoid arthritis. Rheumatology 2000;39:1202-5.
51. Wallberg-Jonsson S, Johansson H, Ohman ML, Rantapaa-Dahlqvist S. Extent of inflammation predicts cardiovascular disease and overall mortality in seropositive rheumatoid arthritis: a retrospective cohort study from disease onset. J Rheumatol 1999;26:2562-71.
52. Reaven GM. Banting Lecture 1988: Role of insulin resistance in human disease. Diabetes 1988;37:1595-607.
53. Svenson KL, Lundqvist G, Wide L, Hallgren R. Impaired glucose handling in active rheumatoid arthritis: relationship to the secretion of insulin and counter-regulatory hormones. Metabolism 1987;36:940-3.
54. Paolisso G, Valentini G, Giugliano D et al. Evidence for peripheral impaired glucose handling in patients with connective tissue diseases. Metabolism 1991;40:902-7.
55. McEntegart A, Capell HA, Creran D et al. Cardiovascular risk factors, including thrombotic variables, in a population with rheumatoid arthritis. Rheumatology 2001;40:640-4.
56. Pope JE, Anderson JJ, Felson DT. A meta-analysis of the effects of non-steroidal anti-inflammatory drugs on blood pressure. Arch Intern Med 1993;153:477-84.
57. Johnson AG, Nguyen TV, Day RO. Do non-steroidal anti-inflammatory drugs affect blood pressure? A meta-analysis. Ann Intern Med 1994;121:289-300.
58. Simon LS, Smolen JS, Abramson SB et al. Controversies in COX-2 selective inhibition. J Rheumatol 2002; 29:1501-10.
59. Collins R, Peto R, MacMahon S et al. Blood pressure, stroke and coronary heart disease. Part 2, short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990; 335:827-38.
60. Adhiyaman V, Asghar M, Oke A, White AD, Shah IU. Nephrotoxicity in the elderly due to co-prescription of angiotensin converting enzyme inhibitors and nonsteroidal anti-inflammatory drugs. J R Soc Med 2001;94:512-4.
61. Situnayake RD, Kitas GD. Dyslipidaemia and rheumatoid arthritis. Ann Rheum Dis 1997;56:341-2.
62. Svenson KL, Lithell H, Hallgren R, Selinus I, Vessby B. Serum lipoprotein in active rheumatoid arthritis and other chronic inflammatory arthritides. I. Relativity to inflammatory activity. Arch Intern Med 1987;147:1912-6.
63. Lakatos I, Harsagyi A. Serum total, HDL, LDL cholesterol, and triglyceride levels in patients with rheumatoid arthritis. Clin Biochem 1988;21:93-6.
64. Lazarevic MB, Vitic I, Mladenovic V, Myones BL, Skosey JL, Swedler WI. Dyslipoproteinemia in the course of active rheumatoid arthritis. Semin Arthritis Rheum 1992; 22:172-8.
65. Rantapaa-Dahlqvist S, Wallberg-Ionsson S, Dahlen G. Lipoprotein (a), lipids, and lipoproteins in patients with rheumatoid arthritis. Ann Rheum Dis 1991;50:366-8.
66. Lee YH, Choi ST, Ji ID, Seo HS, Song GG. Lipoprotein(a) and lipids in relation to inflammation in rheumatoid arthritis. Clin Rheumatol 2000;19:324-5.
67. Svenson KL, Lithell H, Hallgren R, Vessby B. Serum lipoprotein in active rheumatoid arthritis and other chronic inflammatory arthritides. II. Effects of anti-inflammatory and disease-modifying drug treatment. Arch Intern Med 1987;147:1917-20.
68. Mantel-Teeuwisse AK, Kloosterman JME, Maitland-van der Zee AH et al. Drug-induced lipid changes: a review of the unintended effects of some commonly used drugs on serum lipid levels. Drug Safety 2001;24:443-56.
69. Wallace DJ, Metzger AL, Stecher VJ, Turnbull BA, Kern PA. Cholesterol-lowering effect of hydroxychloroquine in patients with rheumatic disease: reversal of deleterious effects of steroids on lipids. Am J Med 1990; 89:322-6.
70. Powrie JK, Shojaee-Moradie F, Watts GF, Smith GD, Sonksen PH, Jones RH. Effects of chloroquine on the dyslipidemia of non-insulin-dependent diabetes mellitus. Metabolism 1993;42:415-9.
71. Petri M, Lakatta C, Magder L, Goldman D. Effect of prednisone and hydroxychloroquine on coronary artery disease risk factors in systemic lupus erythematosus: a longitudinal data analysis. Am J Med 1994;96:254-9.
72. Petri M. Hydroxychloroquine use in the Baltimore Lupus Cohort: effects on lipids, glucose and thrombosis. Lupus 1996;5(Suppl. 1):S16-22.
73. Munro R, Morrison E, McDonald AG, Hunter JA. Madhok R, Capell HA. Effect of disease modifying agents on the lipid profiles of patients with rheumatoid arthritis. Ann Rheum Dis 1997;56:374-7.
74. Tam LS, Gladman DD, Hallett DC, Rahman P, Urowitz MB. Effect of antimalarial agents on the fasting lipid profile in systemic lupus erythematosus. J Rheumatol 2000; 27:2142-5.
75. O'Dell JR, Leff R, Paulsen G et al. Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulphasalazine, or a combination of the three medications: results of a two year, randomised, double-blind, placebo-controlled trial. Arthritis Rheum 2002;46:1164-70.
76. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. J Am Med Assoc 2002;288:321-33.
77. Shepherd J, Cobbe SM, Ford I et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333:1301-7.
78. Downs JR, Clesrfield M, Weis S et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. J Am Med Assoc 1998; 279:1615-22.
79. Law MR, Wald NJ, Thompson SG. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? Br Med J 1994;308:367-72.
80. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: A randomised placebo-controlled trial. Lancet 2002;360:7-22.
81. Frenette PS. Locking a leukocyte integrin with statins. N Engl J Med 2001;345:1419-21.
82. Kwak B, Mulhaupt F, Myit S, Mach F. Statins as a newly recognized type of immunomodulator. Nat Med 2000; 6:1399-402.
83. Munford RS. Statins and the acute phase response. N Engl J Med 2001;344:2016-8.
84. Albert MA, Danielson E, Rifai N, Ridker PM. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. J Am Med Assoc 2001; 286:64-70.
85. Ridker PM, Rifai N, Pfeffer MA et al. and the cholesterol recurrent event investigators. Inflammation, pravastatin, and the risk for coronary events after myocardial infarction in patients with average cholesterol levels. Circulation 1998;98:837-44.
86. Rosenson RS, Tangney CC, Casey CC. Inhibition of proinflammatory cytokine production by pravastatin. Lancet 1999;353:983-4.
87. Tonolo G, Melis MG, Formato M et al. Additive effects of simvastatin beyond its effects on LDL cholesterol in hypertensive type 2 diabetic patients. Eur J Clin Invest 2000;30:980-7.
88. Pasco JA, Kotowicz MA, Henry MJ, Sanders KM, Nicholson GC. Statin use, bone mineral density and fracture risk. Geelong osteoporosis study. Arch Intern Med 2002;162:537-40.
89. Nabel EG. Coronary heart disease in women - an ounce of prevention. N Engl J Med 2000;343:572-4.
90. Aronne LJ. Treating obesity: a new target for prevention of coronary heart disease. Prog Cardiovasc Nurs 2001; 16:98-106.
91. Liu S, Manson JAE. What is the optimal weight for cardiovascular health? Br Med J 2001;322:631-2.
92. Minor MA, Lane NE. Recreational exercise in arthritis. Rheum Dis Clin North Am 1996;22:563-77.
93. Westby MD. A health professional's guide to exercise prescription for people with arthritis: a review of aerobic fitness activities. Arthritis Care Res 2001;45:501-11.
94. van den Ende CHM, Breedveld FC, le Cessie S, Dijkmans BAC, de Mug AW, Hazes JMW. Effect of intensive exercise on patients with active rheumatoid arthritis: a randomised clinical trial. Ann Rheum Dis 2000;59:615-21.
95. Clarke R, Daly L, Robinson K et al. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med 1991;324:1149-55.
96. Boushey CJ, Beresford SA, Omenn GS et al. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. J Am Med Assoc 1995;274:1049-57.
97. Roubenoff R, Dellaripa P, Nadeau MR et al. Abnormal homocysteine metabolism in rheumatoid arthritis. Arthritis Rheum 1997;40:718-22.
98. Morgan SL, Baggott JE, Lee JY, Alarcon GS. Folic acid supplementation prevents deficient blood folate levels and hyperhomocysteinemia during longterm, low dose methotrexate therapy for rheumatoid arthritis: implications for cardiovascular disease prevention. J Rheumatol 1998; 25:441-6.
99. Pettersson T, Friman C, Abrahamsson L, Nilsson B, Norberg B. Serum homocysteine and methylmalonic acid in patients with rheumatoid arthritis and cobalaminopenia. J Rheumatol 1998;25:859-63.
100. Hernanz A, Plaza A, Martin-Mola E, de Miguel E. Increased plasma levels of homocysteine and other thiol compounds in rheumatoid arthritis women. Clin Biochem 1999;32:65-70.
101. Haagsma CJ, Blom HJ, van Riel PL et al. Influence of sulphasalazine, methotrexate, and the combination of both on plasma homocysteine concentrations in patients with rheumatoid arthritis. Ann Rheum Dis 1999;58:79-84.
102. van Ede AE, Laan RFJM, Blom HJ et al. Homocysteine and folate status in methotrexate-treated patients with rheumatoid arthritis. Rheumatology 2002;41:658-65.
103. Landewe RBM, van den Borne BEEM, Breedveld FC, Dijkmans BAC. Methotrexate effects in patients with rheumatoid arthritis with cardiovascular comorbidity. Lancet 2000;355:1616-7.
104. Choi HK, Herman MA, Seeger JD, Robins JM, Wolfe F. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 2002;359:1173-7.
105. Erb N, Kitas GD. Homocysteine modulation as a reason for continuous folic acid supplementation in methotrexate-treated rheumatoid arthritis patients. Rheumatology 2001;40:715-6.
106. Ernst E, Resch K. Fibrinogen as a cardiovascular risk factor: a metaanalysis. Ann Intern Med 1993;118:956-63.
107. Lee AJ, Fowkes FG, Lowe GD et al. Fibrin D-dimer, haemostatic factors and peripheral arterial disease. Thromb Haemost 1995;74:828-32.
108. Wallberg-Jonsson S, Cederfelt M, Rantapaa-Dahlqvist S. Hemostatic factors and cardiovascular disease in active rheumatoid arthritis: an 8 year follow-up study. J Rheumatol 2000;27:71.
109. Wallace DJ, Linker-Israeli M, Metzger AL, Stecher VJ. The relevance of antimalarial therapy with regard to thrombosis, hypercholesterolemia and cytokines in SLE. Lupus 1993;2(Suppl. 1):S13-5.
110. Watson DJ, Rhodes T, Cai B, Guess HA. Lower risk of thromboembolic cardiovascular events with naproxen among patients with rheumatoid arthritis. Arch Intern Med 2002;162:1105-10.
111. Pratico D, Tillmann C, Zhang ZB, Li H, FitzGerald GA. Acceleration of atherogenesis by COX-1-dependent prostanoid formation in low density lipoprotein receptor knockout mice. Proc Natl Acad Sci USA 2001; 98:3358-63.
112. Ko D, Wang Y, Berger AK, Radford MJ, Krumholz HM. Nonsteroidal antiinflammatory drugs after acute myocardial infarction. Am Heart J 2002;143:475-81.
113. Ray WA, Murray KT. Aspirin: redundant in users of nonaspirin, nonsteroidal antiinflammatory agents? Am Heart J 2002;143:381-2.
114. Catella-Lawson F, Reilly MP, Kapoor SC et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001;345:1809-17.
115. Hennan JK, Huang J, Barrett TD et al. Effects of selective cyclooxygenase-2 inhibition on vascular responses and thrombosis in canine coronary arteries. Circulation 2001; 104:820-5.
116. Lipsky PE, Brookes P, Crofford L et al. Unresolved issues in the role of cycloxygenase-2 in normal physiologic processes and disease. Arch Intern Med 2000; 160:913-20.
117. Fitzgerald GA. Cardiovascular pharmacology of non-selective nonsteroidal anti-inflammatory drugs and coxibs: clinical considerations. Am J Cardiol 2002;89 (Suppl.):26D-32D.
118. Bombardier C, Laine L, Reicin A et al., the VIGOR Study Group. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000; 343:1520-8.
119. Mukherjee D, Nissen SE, Topol El. Risk of cardiovascular events associated with selective COX-2 inhibitors. J Am Med Assoc 2001;286:954-9.
120. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999;340:115-26.
121. Sherer Y, Shoenfeld Y. Atherosclerosis. Ann Rheum Dis 2002;61:97-9.
122. Pasceri V, Yeh ETH. A tale of two diseases. Atherosclerosis and rheumatoid arthritis. Circulation 1999; 100:2124-6.
123. Liuzzo G, Kopecky SL, Frye RL et al. Perturbation of the T-cell repertoire in patients with unstable angina. Circulation 1999;100:2135-9.
124. Liuzzo G, Goronzy JJ, Yang H et al. Monoclonal T cell proliferation and plaque instability in acute coronary syndromes. Circulation 2000;102:2883-8.
125. Kitas GD, Banks MJ, Bacon PA. Accelerated atherosclerosis as a cause of cardiovascular death in RA. Pathogenesis 1998;1:73-83.
126. Mach P, Schonbeck U, Sukhova GK, Atkinson E, Libby P. Reduction of atherosclerosis in mice by inhibition of CD40 signalling. Nature 1998;394:200-3.
127. Nicoletti A, Kaveri S, Caligiuri G, Bariety J, Hansson GK. Immunoglobulin treatment reduces atherosclerosis in apo E knockout mice. J Clin Invest 1998;102:910-8.
128. Zhou X, Nicoletti A, Elhage R, Hansson GK. Transfer of CD4(+) T cells aggravates atherosclerosis in immunodeficient apolipoprotein E knockout mice. Circulation 2000;102:2919-22.
129. Nicoletti A, Paulsson G, Caligiuri G, Zhou X, Hansson GK. Induction of neonatal tolerance to oxidized lipoprotein reduces atherosclerosis in ApoE knockout mice. Mol Med 2000;6:283-90.
130. Rader DJ. Inflammatory markers of coronary risk. N Engl J Med 2000;343:1179-82.
131. Koenig W. Heart disease and the inflammatory response. Br Med J 2000;321:187-8.
132. Danesh J, Whincup P, Walker M et al. Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. Br Med J 2000;321:199-204.
133. Morrow DA, Ridker PM. C-reactive protein, inflammation and coronary risk. Med Clin North Am 2000; 84:149-61.
134. Jacobsson LT, Turesson C, Hanson RL et al. Joint swelling as a predictor of death from cardiovascular disease in a population study of Pima Indians. Arthritis Rheum 2001;44:1170-6.
135. Chehata JC, Hassell AB, Clarke SA et al. Mortality in rheumatoid arthritis: relation to single and composite measures of disease activity. Rheumatology 2001;40:447-52.
136. Mitchell DM, Spitz PW, Young DY, Bloch DA, McShane DJ, Fries JF. Survival, prognosis, and causes of death in rheumatoid arthritis. Arthritis Rheum 1986;29:706-14.
137. Lehtinen K, Isomaki H. Intramuscular gold therapy is associated with long survival in patients with rheumatoid arthritis. J Rheumatol 1991;18:524-9.
138. Krause D, Schleusser B, Herborn G, Rau R. Response to methotrexate treatment is associated with reduced mortality in patients with severe rheumatoid arthritis. Arthritis Rheum 2000;43:14-21.
139. Bierman EL. Atherogenesis in diabetes. Arterioscler Thromb 1992;12:647-56.
140. Turner RC, Millns H, Neil HAW et al. for the United Kingdom Prospective Diabetes Study Group. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: UK prospective diabetes study (UKPD:23). Br Med J 1998;316:823-8.
141. Joint British recommendations on prevention of coronary heart disease in clinical practice: summary. British Cardiac Society, British Hyperlipidaemia Association, British Hypertension Society, British Diabetic Association. Br Med J 2000;320:705-8.